Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 7/20 | 0.35 |
| ▸ | UBE2M | P61081 | 3/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708889 | 0.85 | KCNH2 (0.35) | — | |
| SCHEMBL707961 | 0.82 | KCNH2 (0.40) | OPRM1TMEM97CCR5CCR3 | |
| SCHEMBL3100183 | 0.81 | OPRM1 (0.37) | OPRM1TMEM97 | |
| SCHEMBL707084 | 0.81 | DRD2 (0.42) | OPRM1CCR5TACR1 | |
| SCHEMBL705075 | 0.78 | KCNH2 (0.36) | OPRM1TMEM97UBE2MDCUN1D1CCR3 | |
| SCHEMBL922023 | 0.78 | SIGMAR1 (0.40) | CCR3 | |
| SCHEMBL708897 | 0.78 | KCNH2 (0.37) | CCR5 | |
| SCHEMBL706977 | 0.78 | KCNH2 (0.40) | CCR5 | |
| SCHEMBL707605 | 0.77 | SPHK1 (0.36) | HTR2A | |
| SCHEMBL706408 | 0.77 | KCNH2 (0.34) | OPRM1TMEM97UBE2MDCUN1D1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | OPRM1 2772/4885TMEM97 3100/4885CCR5 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.